| Gastric cancer: a comprehensive review of current and future treatment strategies RE Sexton, MN Al Hallak, M Diab, AS Azmi Cancer and Metastasis Reviews 39 (4), 1179-1203, 2020 | 446 | 2020 |
| KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? M Nagasaka, Y Li, A Sukari, SHI Ou, MN Al-Hallak, AS Azmi Cancer treatment reviews 84, 101974, 2020 | 183 | 2020 |
| Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer M Nagasaka, MH Uddin, MN Al-Hallak, S Rahman, S Balasubramanian, ... Molecular Cancer 20, 1-16, 2021 | 74 | 2021 |
| [18F]-FDG uptake dose–response correlates with radiation pneumonitis in lung cancer patients MR McCurdy, R Castillo, J Martinez, MN Al Hallack, J Lichter, N Zouain, ... Radiotherapy and Oncology 104 (1), 52-57, 2012 | 59 | 2012 |
| Targeting KRAS in pancreatic cancer: new drugs on the horizon SF Bannoura, MH Uddin, M Nagasaka, F Fazili, MN Al-Hallak, PA Philip, ... Cancer and Metastasis Reviews, 1-17, 2021 | 58 | 2021 |
| Gastrointestinal stromal tumor: a review of current and emerging therapies B Al-Share, A Alloghbi, MN Al Hallak, H Uddin, A Azmi, RM Mohammad, ... Cancer and Metastasis Reviews 40, 625-641, 2021 | 53 | 2021 |
| Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma AS Azmi, HY Khan, I Muqbil, A Aboukameel, JE Neggers, D Daelemans, ... Clinical Cancer Research 26 (6), 1338-1348, 2020 | 37 | 2020 |
| Calcium release-activated calcium (CRAC) channel inhibition suppresses pancreatic ductal adenocarcinoma cell proliferation and patient-derived tumor growth HY Khan, GB Mpilla, R Sexton, S Viswanadha, KV Penmetsa, ... Cancers 12 (3), 750, 2020 | 31 | 2020 |
| Exosomal microRNA in pancreatic cancer diagnosis, prognosis, and treatment: from bench to bedside MH Uddin, MN Al-Hallak, PA Philip, RM Mohammad, N Viola, KU Wagner, ... Cancers 13 (11), 2777, 2021 | 30 | 2021 |
| Gastric cancer heterogeneity and clinical outcomes RE Sexton, MNA Hallak, MH Uddin, M Diab, AS Azmi Technology in Cancer Research & Treatment 19, 1533033820935477, 2020 | 29 | 2020 |
| Extramammary perianal Paget’s disease MN Al Hallak, N Zouain Case Reports in Gastroenterology 3 (3), 332-337, 2009 | 25 | 2009 |
| Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer I Azar, S Alkassis, J Fukui, F Alsawah, K Fedak, MN Al Hallak, A Sukari, ... Lung Cancer: Targets and Therapy, 103-114, 2021 | 23 | 2021 |
| PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus GB Mpilla, MH Uddin, MN Al-Hallak, A Aboukameel, Y Li, SH Kim, ... Molecular cancer therapeutics 20 (10), 1836-1845, 2021 | 18 | 2021 |
| Non-coding RNAs in pancreatic cancer diagnostics and therapy: focus on lncRNAs, circRNAs, and piRNAs Y Li, MN Al Hallak, PA Philip, AS Azmi, RM Mohammad Cancers 13 (16), 4161, 2021 | 18 | 2021 |
| Primary submucosal squamous cell carcinoma of the rectum diagnosed by endoscopic ultrasound: case report and literature review MN Al Hallak, G Hage-Nassar, A Mouchli Case reports in gastroenterology 4 (2), 243-249, 2010 | 18 | 2010 |
| Connecting the human microbiome and pancreatic cancer RE Sexton, MH Uddin, S Bannoura, HY Khan, Y Mzannar, Y Li, ... Cancer and Metastasis Reviews 41 (2), 317-331, 2022 | 13 | 2022 |
| Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C–mutant cancers HY Khan, M Nagasaka, Y Li, A Aboukameel, MH Uddin, R Sexton, ... Cancer research communications 2 (5), 342-352, 2022 | 13 | 2022 |
| Risk and surveillance of cancers in primary biliary tract disease V Hrad, Y Abebe, SH Ali, J Velgersdyk, M Al Hallak, M Imam Gastroenterology research and practice 2016, 2016 | 13 | 2016 |
| Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset M Nagasaka, D Brazel, Y Baca, J Xiu, MN Al-Hallak, C Kim, J Nieva, ... Translational Oncology 36, 101744, 2023 | 6 | 2023 |
| Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208. P Spiliopoulou, A Kasi, LI Abushahin, DB Cardin, HJ Lenz, F Dayyani, ... Journal of Clinical Oncology 40 (16_suppl), 4136-4136, 2022 | 6 | 2022 |
Md Hafiz UddinResearch Scientist, Karmanos Cancer Institute, Wayne State University, Detroit, MIVerified email at snu.ac.kr
